- Home
- ABTS vs SYBX Comparison
ABTS vs SYBX Comparison
Compare ABTS & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABTS
- SYBX
- Stock Information
- Founded
- ABTS 2010
- SYBX N/A
- Country
- ABTS Hong Kong
- SYBX United States
- Employees
- ABTS N/A
- SYBX N/A
- Industry
- ABTS Computer Software: Programming Data Processing
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- ABTS Technology
- SYBX Health Care
- Exchange
- ABTS Nasdaq
- SYBX Nasdaq
- Market Cap
- ABTS 15.9M
- SYBX 16.5M
- IPO Year
- ABTS N/A
- SYBX N/A
- Fundamental
- Price
- ABTS $0.47
- SYBX $1.37
- Analyst Decision
- ABTS
- SYBX Hold
- Analyst Count
- ABTS 0
- SYBX 3
- Target Price
- ABTS N/A
- SYBX $1.00
- AVG Volume (30 Days)
- ABTS 76.0K
- SYBX 22.9K
- Earning Date
- ABTS 12-31-2024
- SYBX 03-18-2025
- Dividend Yield
- ABTS N/A
- SYBX N/A
- EPS Growth
- ABTS N/A
- SYBX N/A
- EPS
- ABTS N/A
- SYBX N/A
- Revenue
- ABTS $5,343,888.00
- SYBX $2,777,000.00
- Revenue This Year
- ABTS N/A
- SYBX N/A
- Revenue Next Year
- ABTS N/A
- SYBX N/A
- P/E Ratio
- ABTS N/A
- SYBX N/A
- Revenue Growth
- ABTS 3970.67
- SYBX 292.23
- 52 Week Low
- ABTS $0.38
- SYBX $1.22
- 52 Week High
- ABTS $1.07
- SYBX $3.70
- Technical
- Relative Strength Index (RSI)
- ABTS 46.52
- SYBX 42.19
- Support Level
- ABTS $0.44
- SYBX $1.26
- Resistance Level
- ABTS $0.59
- SYBX $1.44
- Average True Range (ATR)
- ABTS 0.04
- SYBX 0.08
- MACD
- ABTS -0.00
- SYBX -0.01
- Stochastic Oscillator
- ABTS 21.85
- SYBX 43.48
About ABTS Abits Group Inc
Abits Group Inc is a digital data center operator with bitcoin self-mining operations.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.